GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » Debt-to-EBITDA

JCR Pharmaceuticals Co (TSE:4552) Debt-to-EBITDA : 21.26 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

JCR Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円9,700 Mil. JCR Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円13,600 Mil. JCR Pharmaceuticals Co's annualized EBITDA for the quarter that ended in Dec. 2023 was 円1,096 Mil. JCR Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 21.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for JCR Pharmaceuticals Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4552' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.82   Med: 1.09   Max: 3.09
Current: 3.09

During the past 13 years, the highest Debt-to-EBITDA Ratio of JCR Pharmaceuticals Co was 3.09. The lowest was 0.82. And the median was 1.09.

TSE:4552's Debt-to-EBITDA is ranked worse than
65.65% of 658 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs TSE:4552: 3.09

JCR Pharmaceuticals Co Debt-to-EBITDA Historical Data

The historical data trend for JCR Pharmaceuticals Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co Debt-to-EBITDA Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 1.71 0.85 3.06 -

JCR Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.86 2.56 1.19 21.26 -

Competitive Comparison of JCR Pharmaceuticals Co's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Debt-to-EBITDA falls into.



JCR Pharmaceuticals Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

JCR Pharmaceuticals Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

JCR Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9700 + 13600) / 1096
=21.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


JCR Pharmaceuticals Co  (TSE:4552) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


JCR Pharmaceuticals Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


JCR Pharmaceuticals Co (TSE:4552) Business Description

Traded in Other Exchanges
Address
3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines